Invasive Aspergillosis Trial May Include Non-Licensed Comparator - FDA
Executive Summary
FDA is considering use of liposomal amphotericin B products as a comparator in first-line invasive aspergillosis trials, FDA Special Pathogens & Immunologic Drug Products Division Director Mark Goldberger, MD, indicated Jan. 10.